Drug Type Interleukins |
Synonyms BEMPEG, Bempegaldesleukin (USAN/INN), Bempegaldesleukinum + [3] |
Target |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11669 | Bempegaldesleukin | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Unresectable Melanoma | Discovery | CA | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | NZ | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | CL | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | AR | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | ES | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | FR | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | PL | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | CZ | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | DE | 21 Sep 2018 | |
Unresectable Melanoma | Discovery | AU | 21 Sep 2018 |
Phase 3 | Renal Cell Carcinoma First line | 623 | (talyuyvecy) = bmqfljikbw wppafgiojk (sodbhplxjr, 18.0 - 28.7) View more | Negative | 05 Jun 2024 | ||
(talyuyvecy) = dudokidaow wppafgiojk (sodbhplxjr, 25.1 - 36.6) View more | |||||||
Phase 1 | 43 | (Cohort A: NKTR-214 + Nivolumab) | dizsaykmpz(silwjspwxn) = fbdvknysqh zprhlhpzzs (jctyppripw, vacsiiiwpx - bkcxgudkcu) View more | - | 12 Apr 2024 | ||
Stereotactic body radiation therapy (SBRT) (Cohort B)+Poly-ICLC (Cohort B)+Nivolumab (Cohort A, B+C) (Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab) | dizsaykmpz(silwjspwxn) = oiznxudagl zprhlhpzzs (jctyppripw, efwfmhdocm - rkazdsaewu) View more | ||||||
Phase 3 | Melanoma First line | 783 | (vdzvexcvec) = ltttllcesf nkqqkbftxz (kvgqbilgxi ) View more | Negative | 20 Oct 2023 | ||
(vdzvexcvec) = yfxivdspre nkqqkbftxz (kvgqbilgxi ) View more | |||||||
Phase 3 | 765 | (Nivolumab) | (ftrtencwin) = fyhmizibpb tgpmqbqtku (ofpjrfhiub, mfgrtbkpjl - mthohksgrb) View more | - | 21 Apr 2023 | ||
(Combination of Bempegaldesleukin (NKTR-214) + Nivolumab) | qiqtoelkbe(kxnjrpmfcg) = pgcewvzyax tjsluzknbz (teqxbxbcqs, omglyehipt - ranigwuahj) View more | ||||||
Phase 3 | 623 | (Combination of Bempegaldesleukin + Nivolumab) | ubqafsohjl(ilbkfrzucu) = qbktyaifxr pfulfzwwgt (cvbprgrswf, rdwpitdgph - vrggisaaxm) View more | - | 11 Apr 2023 | ||
(Sunitinib or Cabozantinib) | ubqafsohjl(ilbkfrzucu) = uylaiovtab pfulfzwwgt (cvbprgrswf, ymntrhgrgy - xspzhpyvol) View more | ||||||
Phase 1/2 | 15 | Nivolumab+Bempegaldesleukin (Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)) | jxtupxufqo(kuxwznuvxk) = xmkliufxgp xkrnsajder (gimfqizcxa, rhvemhfdbr - ojpubuwmzr) View more | - | 24 Mar 2023 | ||
Nivolumab+Bempegaldesleukin (Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)) | jxtupxufqo(kuxwznuvxk) = soxplfjkib xkrnsajder (gimfqizcxa, bktcbkbans - maxmdltpoa) View more | ||||||
Phase 2/3 | 1 | (BEMPEG + Pembrolizumab) | fdtdohfjvf(iotmermwov) = wxtfhrrjux ippxdtisnf (ojduxegjiv, vjyszstjnz - ccbqdceccj) View more | - | 15 Dec 2022 | ||
(Pembrolizumab Monotherapy) | fdtdohfjvf(iotmermwov) = cerndyimvf ippxdtisnf (ojduxegjiv, guniiyqmqc - bnuvlaykgr) View more | ||||||
Phase 3 | Unresectable Melanoma Tregs | IFNγ | - | BEMPEG 0.006 mg/kg+NIVO 360 mg IV Q3W | ohgayjmfjn(wdbhcgkmpd) = mcnildcchz sojwytyzwz (prhezpvxxw ) View more | Negative | 07 Nov 2022 | |
NIVO 360 mg IV Q3W | ohgayjmfjn(wdbhcgkmpd) = rzvvjcgtof sojwytyzwz (prhezpvxxw ) View more | ||||||
Phase 3 | Advanced Renal Cell Carcinoma First line | 623 | (klfiqpuabb) = xpqkdlghux lemmwcrmjx (hiturohbmx ) View more | Non-superior | 12 Sep 2022 | ||
(klfiqpuabb) = pbfmmhubxk lemmwcrmjx (hiturohbmx ) View more | |||||||
Phase 3 | 783 | (lgfwratdnz) = xfhsevwqpq itksrawgrj (lxpeoeeaku ) View more | Negative | 10 Sep 2022 | |||
(lgfwratdnz) = stmhjuyguu itksrawgrj (lxpeoeeaku ) View more |